PL2819648T3 - Preparat farmaceutyczny zawierający pochodną dihydrochinazoliny o działaniu przeciwwirusowym - Google Patents

Preparat farmaceutyczny zawierający pochodną dihydrochinazoliny o działaniu przeciwwirusowym

Info

Publication number
PL2819648T3
PL2819648T3 PL13707000T PL13707000T PL2819648T3 PL 2819648 T3 PL2819648 T3 PL 2819648T3 PL 13707000 T PL13707000 T PL 13707000T PL 13707000 T PL13707000 T PL 13707000T PL 2819648 T3 PL2819648 T3 PL 2819648T3
Authority
PL
Poland
Prior art keywords
antiviral
pharmaceutical preparation
dihydroquinazoline derivative
dihydroquinazoline
derivative
Prior art date
Application number
PL13707000T
Other languages
English (en)
Inventor
Kerstin Paulus
Wilfried Schwab
Dominique Grunder
Hoogevest Peter Van
Original Assignee
Aicuris Anti Infective Cures Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47757622&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2819648(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aicuris Anti Infective Cures Gmbh filed Critical Aicuris Anti Infective Cures Gmbh
Publication of PL2819648T3 publication Critical patent/PL2819648T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/78Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL13707000T 2012-02-29 2013-02-28 Preparat farmaceutyczny zawierający pochodną dihydrochinazoliny o działaniu przeciwwirusowym PL2819648T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102012101680A DE102012101680A1 (de) 2012-02-29 2012-02-29 Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat
EP13707000.9A EP2819648B1 (de) 2012-02-29 2013-02-28 Pharmazeutische zubereitung enthaltend ein antiviral wirksames dihydrochinazolinderivat
PCT/EP2013/054114 WO2013127970A1 (de) 2012-02-29 2013-02-28 Pharmazeutische zubereitung enthaltend ein antiviral wirksames dihydrochinazolinderivat

Publications (1)

Publication Number Publication Date
PL2819648T3 true PL2819648T3 (pl) 2019-10-31

Family

ID=47757622

Family Applications (2)

Application Number Title Priority Date Filing Date
PL13707000T PL2819648T3 (pl) 2012-02-29 2013-02-28 Preparat farmaceutyczny zawierający pochodną dihydrochinazoliny o działaniu przeciwwirusowym
PL19176985.0T PL3556350T3 (pl) 2012-02-29 2013-02-28 Preparat farmaceutyczny zawierający pochodną dihydrochinazoliny o działaniu przeciwwirusowym mającą konfigurację s w pozycji 4

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL19176985.0T PL3556350T3 (pl) 2012-02-29 2013-02-28 Preparat farmaceutyczny zawierający pochodną dihydrochinazoliny o działaniu przeciwwirusowym mającą konfigurację s w pozycji 4

Country Status (37)

Country Link
US (1) US10603384B2 (pl)
EP (3) EP4328218A3 (pl)
JP (1) JP6387486B2 (pl)
KR (1) KR102149561B1 (pl)
CN (2) CN104144678A (pl)
AU (1) AU2013224947B2 (pl)
BR (1) BR112014020946B1 (pl)
CA (1) CA2865203C (pl)
CL (1) CL2014002306A1 (pl)
CO (1) CO7061076A2 (pl)
CY (1) CY1121910T1 (pl)
DE (1) DE102012101680A1 (pl)
DK (2) DK3556350T3 (pl)
EA (1) EA026584B1 (pl)
ES (2) ES2741698T3 (pl)
FI (1) FI3556350T3 (pl)
HK (1) HK1205462A1 (pl)
HR (2) HRP20240197T1 (pl)
HU (1) HUE045949T2 (pl)
IL (1) IL234363B (pl)
IN (1) IN2014MN01892A (pl)
LT (2) LT2819648T (pl)
MA (1) MA35941B1 (pl)
ME (1) ME03448B (pl)
MX (1) MX369666B (pl)
MY (1) MY172310A (pl)
NZ (1) NZ628444A (pl)
PH (1) PH12014501937A1 (pl)
PL (2) PL2819648T3 (pl)
PT (2) PT3556350T (pl)
RS (2) RS65137B1 (pl)
SG (1) SG11201405294XA (pl)
SI (2) SI3556350T1 (pl)
TN (1) TN2014000345A1 (pl)
UA (1) UA111415C2 (pl)
WO (1) WO2013127970A1 (pl)
ZA (1) ZA201405949B (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10319612A1 (de) 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
LT3010891T (lt) * 2013-06-19 2019-08-26 Aicuris Anti-Infective Cures Gmbh Amorfinis letermoviras ir jo kietos farmacinės kompozicijos, skirtos peroraliniam įvedimui
SG11201810836PA (en) 2016-06-03 2018-12-28 Atreya Innovations Private Ltd A device for the detection and reliable capturing of the pulse characteristics
SG11201908181XA (en) 2017-03-06 2019-10-30 Venatorx Pharmaceuticals Inc Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
UY39099A (es) 2020-02-27 2021-08-31 Aic246 Gmbh & Co Kg 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio y composiciones farmacéuticas del mismo
UY39095A (es) 2020-02-27 2021-09-30 Aic246 Gmbh & Co Kg Composiciones farmacéuticas que comprenden acetato de 2- [(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il] e iones de sodio
CN114539085B (zh) * 2020-11-26 2023-10-20 山东诚创蓝海医药科技有限公司 一种脲基衍生物的制备
CN115403528A (zh) * 2021-05-27 2022-11-29 南京正大天晴制药有限公司 无定形3,4-二氢喹唑啉衍生物的制备方法
CN113880776B (zh) * 2021-11-16 2023-06-16 山东诚创蓝海医药科技有限公司 一种莱特莫韦中间体的制备方法
AR128035A1 (es) 2021-12-21 2024-03-20 Aic246 Ag & Co Kg Composiciones farmacéuticas que comprenden acetato de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] e iones de potasio
CN115322157B (zh) * 2022-06-02 2023-12-05 浙江车头制药股份有限公司 来特莫韦中间体化合物及其制备方法和应用
CN115677539B (zh) * 2022-11-01 2023-10-24 南京工业大学 一种温和条件下钴催化脲基导向芳烃的高选择性单烯基化的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1242699A (en) * 1985-02-01 1988-10-04 Bristol-Myers Company Cefbuperazone and derivatives thereof
CA1284994C (en) * 1985-08-05 1991-06-18 Murray Arthur Kaplan Cephalosporin salts and injectable compositions
JP3552240B2 (ja) * 1993-02-23 2004-08-11 第一製薬株式会社 高濃度tcf製剤
JPH11209277A (ja) * 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
IT1304190B1 (it) * 1998-12-18 2001-03-08 Euphar Group Srl Clatrati di deidroepiandrosterone e relative composizionifarmaceutiche
SK287238B6 (sk) * 1999-03-17 2010-04-07 Astrazeneca Ab Amidové deriváty, spôsob ich prípravy, farmaceutická kompozícia, ktorá ich obsahuje, a ich použitie
WO2001091751A1 (en) * 2000-05-30 2001-12-06 Novo Nordisk A/S New pharmaceutical composition and the process for its preparation
DE10319612A1 (de) 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
US7939539B2 (en) * 2003-11-25 2011-05-10 Novartis Vaccines And Diagnostics, Inc. Quinazolinone compounds as anticancer agents
EP1846410B1 (en) * 2005-02-10 2009-01-21 Bristol-Myers Squibb Company Dihydroquinazolinones as 5ht modulators
DE102005027517A1 (de) 2005-06-15 2006-12-21 Bayer Healthcare Ag Verfahren zur Herstellung von Dihydrochinazolinen
US8743287B2 (en) * 2009-07-24 2014-06-03 Broadcom Corporation Method and system for mitigating motion trail artifacts and improving low contrast contours in temporal filtering based noise reduction

Also Published As

Publication number Publication date
WO2013127970A1 (de) 2013-09-06
AU2013224947A1 (en) 2014-09-18
EA201400963A1 (ru) 2015-02-27
EP3556350A1 (de) 2019-10-23
EP4328218A3 (de) 2024-04-10
HRP20240197T1 (hr) 2024-04-26
CL2014002306A1 (es) 2014-11-28
HRP20191369T1 (hr) 2019-11-01
EP4328218A2 (de) 2024-02-28
ZA201405949B (en) 2021-07-28
CA2865203C (en) 2019-11-05
ME03448B (me) 2020-01-20
US20150133461A1 (en) 2015-05-14
CY1121910T1 (el) 2020-10-14
PT3556350T (pt) 2024-02-15
LT3556350T (lt) 2024-02-26
PL3556350T3 (pl) 2024-05-06
PH12014501937A1 (en) 2014-11-24
JP2015508801A (ja) 2015-03-23
HUE045949T2 (hu) 2020-01-28
KR20140130683A (ko) 2014-11-11
SG11201405294XA (en) 2014-11-27
EP2819648A1 (de) 2015-01-07
UA111415C2 (uk) 2016-04-25
HK1205462A1 (en) 2015-12-18
BR112014020946B1 (pt) 2022-04-05
DK3556350T3 (da) 2024-02-12
IN2014MN01892A (pl) 2015-07-10
RS65137B1 (sr) 2024-02-29
SI3556350T1 (sl) 2024-03-29
CO7061076A2 (es) 2014-09-19
IL234363B (en) 2020-04-30
CN104144678A (zh) 2014-11-12
FI3556350T3 (fi) 2024-02-14
LT2819648T (lt) 2019-09-10
DK2819648T3 (da) 2019-08-26
ES2741698T3 (es) 2020-02-12
RS59157B1 (sr) 2019-10-31
EP3556350B1 (de) 2024-01-10
AU2013224947B2 (en) 2017-06-29
TN2014000345A1 (en) 2015-12-21
CN110433166A (zh) 2019-11-12
MY172310A (en) 2019-11-21
NZ628444A (en) 2016-07-29
DE102012101680A1 (de) 2013-08-29
PT2819648T (pt) 2019-09-05
EP2819648B1 (de) 2019-05-29
JP6387486B2 (ja) 2018-09-12
MX2014010364A (es) 2014-12-05
BR112014020946A2 (pl) 2017-06-20
CA2865203A1 (en) 2013-09-06
ES2972133T3 (es) 2024-06-11
KR102149561B1 (ko) 2020-08-31
SI2819648T1 (sl) 2019-10-30
MX369666B (es) 2019-11-14
MA35941B1 (fr) 2014-12-01
EA026584B1 (ru) 2017-04-28
US10603384B2 (en) 2020-03-31

Similar Documents

Publication Publication Date Title
HK1203884A1 (en) Atomiser system
IL236024A (en) The history of benzimidazole-proline and its pharmaceutical preparations
EP2891658A4 (en) PRODRUCE OF TENOFOVIR AND ASSOCIATED PHARMACEUTICAL USES THEREOF
PT2819648T (pt) Preparação farmacêutica compreendendo um derivado antiviral de di-hidroquinazolina
HK1203812A1 (en) Novel pharmaceutical formulations
HK1205146A1 (en) Pharmaceutical formulation
ZA201405797B (en) Pharmaceutical dosage form
AP2015008208A0 (en) Pharmaceutical administration forms comprising
HK1205683A1 (en) Pharmaceutical formulation having improved stability
HK1215789A1 (zh) 藥物組合
HK1220633A1 (zh) 含有氨基吡唑衍生物的藥物製劑
HK1209339A1 (en) Pharmaceutical formulations
GB201217990D0 (en) Antiviral drug derivatives
ZA201502354B (en) Pharmaceutical dosage form
PL394696A1 (pl) Pochodna leku przeciwwirusowego
GB201211403D0 (en) Pharmaceutical formulations
GB201211406D0 (en) Pharmaceutical formulations
GB201121968D0 (en) Antiviral drug derivatives
GB201121966D0 (en) Antiviral drug derivatives